Meridien Research — Spring Hill, Florida

Meridien Research is a clinical research site located in Spring Hill, Florida, United States 34609.

Crixeo Clinical Trials Trust Score: 14/100 (FAILING). This profile has not yet been claimed by the site owner.

Meridien Research has participated in 6 clinical trials.

Therapeutic areas: Overactive Bladder, Alzheimer's Disease, Migraine, With or Without Aura.

Sponsors: Urovant Sciences GmbH, Eli Lilly and Company, Allergan.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Spring Hill

Browse all research sites in Florida · View every site in Spring Hill

• Asclepes Research Centers
• Florida Cancer Specialists
• GSK Investigational Site
• Novo Nordisk Investigational Site
• Pfizer Investigational Site
• Asclepes Research Center
• Clinical Research of Tampa Bay, Inc.
• Florida Sleep Institute
• Duramed Investigational Site
• Research Site
• Novel Outcomes Research

Sponsor Feasibility Report

Trust Score: 14/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Meridien Research?

Meridien Research has a Crixeo Trust Score of 14/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Meridien Research conducted?

Meridien Research has 6 clinical trials on record. Their work covers Overactive Bladder, Alzheimer's Disease, Migraine, With or Without Aura.

Is Meridien Research accredited by Crixeo Clinical Trials?

Meridien Research has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Meridien Research?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.